A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries

PLoS Medicine

Volumn 12, Issue 3, 2015, Pages

  Suthar, Amitabh B ^a   Harries, Anthony D ^b,c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 493; ABT 530; ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; EFAVIRENZ; ELBASVIR; FALDAPREVIR; GRAZOPREVIR; GS 5816; GS 9669; LEDIPASVIR; MERICITABINE; OMBITASVIR; PARITAPREVIR; PPI 668; RIFAMPICIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VANIPREVIR; VEDROPREVIR; VX 135;

ARTICLE; DIAGNOSTIC TEST; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMIC ASPECT; HEPATITIS C; INCOME; INFECTION CONTROL; LIVER CIRRHOSIS; MASS SCREENING; MORTALITY; PREVALENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS TRANSMISSION; DEVELOPING COUNTRY; HEPACIVIRUS; HUMAN; PUBLIC HEALTH; TRANSMISSION; VIROLOGY;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INCOME; PUBLIC HEALTH;

EID: 84926435481     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001795     Document Type: Article

References (75)

1. World Health Organization. Hepatitis C. 2014 [cited 21 May 2014].http://www.who.int/mediacentre/factsheets/fs164/en/
2. Thomas DL, Seeff LB, Natural history of hepatitis C. Clin Liver Dis. 2005; 9(3): 383–98, vi. 16023972
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H, Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1S): S45–S57.
4. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–71. 25530442
5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST, Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333–42. doi: 10.1002/hep.26141 23172780
6. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology. 2015; 61(1): 77–87. doi: 10.1002/hep.27259 25069599
7. Sixty-Seventh World Health Assembly. Hepatitis. 2014 [cited 30 July 2014]; http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf
8. Feeney ER, Chung RT, Antiviral treatment of hepatitis C. BMJ. 2014; 349: g3308. doi: 10.1136/bmj.g3308 25002352
9. Kohli A, Shaffer A, Sherman A, Kottilil S, Treatment of hepatitis C: a systematic review. JAMA. 2014; 312(6): 631–40. doi: 10.1001/jama.2014.7085 25117132
10. Liang TJ, Ghany MG, Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368(20): 1907–17. doi: 10.1056/NEJMra1213651 23675659
11. United Nations. Open Working Group proposal for Sustainable Development Goals. 2014 [cited 31 January 2015; https://sustainabledevelopment.un.org/content/documents/1579SDGs%20Proposal.pdf
12. UNITAID. Hepatitis C Medicines: Technology and Market Landscape. 2015 [cited 14 February 2015]; http://www.unitaid.eu/images/marketdynamics/publications/HCV_Meds_Landscape_Feb2015.pdf
13. World Hepatitis Alliance. 2015 Strategic Plan. 2015 [cited 31 January 2015]; http://www.worldhepatitisalliance.org/files/worldhepatitisalliance/downloads/News/reports%20and%20accounts/Strategic%20Plan%202015.pdf
14. Treatment Action Group. Global Update: Hepatitis C Treatment Activism. 2014 [cited 3 December 2014]; http://www.pipelinereport.org/sites/g/files/g575521/f/201407/HCV%20Global%20Activism.pdf
15. Medecins Sans Frontieres. The Diagnosis and Treatment of Hepatitis C: A Technical Landscape. 2014 [cited 24 July 2014]; http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/MSF%20HCV%20landscape.pdf
16. Initiative for Medicines Access and Knowledge. Legal Documents for Opposition to Sofosbuvir in India. 2014 [cited 3 December 2014]; http://www.i-mak.org/sofosbuvir/
17. Bridge J, Hunter BM, Atun R, Lazarus JV, Global Fund investments in harm reduction from 2002 to 2009. Int J Drug Policy. 2012; 23(4): 279–85. doi: 10.1016/j.drugpo.2012.01.013 22421551
18. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011; 377(9782): 2031–41. doi: 10.1016/S0140-6736(11)60702-2 21641026
19. World Health Organization. The Recife Political Declaration on Human Resources for Health. 2013 [cited; http://www.who.int/workforcealliance/forum/2013/recife_declaration_17nov.pdf
20. Dybul M, Piot P, Frenk J, Reshaping Global Health. Hoover Institution Policy Review. 2012; 173(June).
21. Kim JY, Farmer P, Porter ME, Redefining global health-care delivery. Lancet. 2013; 382(9897): 1060–9. doi: 10.1016/S0140-6736(13)61047-8 23697823
22. Birx D, de Souza M, Nkengasong JN, Laboratory challenges in the scaling up of HIV, TB, and malaria programs: The interaction of health and laboratory systems, clinical research, and service delivery. Am J Clin Pathol. 2009; 131(6): 849–51. doi: 10.1309/AJCPGH89QDSWFONS 19461092
23. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ, Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis. Clin Infect Dis. 2014; 59(6): 765–73. doi: 10.1093/cid/ciu447 24928290
24. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M, Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012; 88(7): 558–64. doi: 10.1136/sextrans-2012-050566 22859499
25. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 Suppl 2: 61–80. doi: 10.1111/j.1478-3231.2011.02540.x 21651703
26. Madhava V, Burgess C, Drucker E, Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002; 2(5): 293–302. 12062995
27. Kershenobich D, Razavi HA, Sanchez-Avila JF, Bessone F, Coelho HS, Dagher L, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011; 31 Suppl 2: 18–29. doi: 10.1111/j.1478-3231.2011.02538.x 21651701
28. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011; 31 Suppl 2: 30–60. doi: 10.1111/j.1478-3231.2011.02539.x 21651702
29. Hope VD, Eramova I, Capurro D, Donoghoe MC, Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014; 142(2): 270–86. doi: 10.1017/S0950268813000940 23714072
30. World Health Organization. Screening Donated Blood for Transfusion-Transmissible Infections. 2010 [cited 18 July 2014]; http://www.who.int/bloodsafety/ScreeningDonatedBloodforTransfusion.pdf.
31. World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings. 2015 [cited 23 February 2015]; http://www.who.int/injection_safety/global-campaign/injection-safety_guidline.pdf
32. Phillips EK, Conaway MR, Jagger JC, Percutaneous injuries before and after the Needlestick Safety and Prevention Act. N Engl J Med. 2012; 366(7): 670–1. doi: 10.1056/NEJMc1110979 22335760
33. World Health Organization. Guidance on prevention of viral hepatitis B and C among people who inject drugs. 2012 [cited 26 May 2014]; http://www.who.int/iris/bitstream/10665/75357/1/9789241504041_eng.pdf
34. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192(11): 1880–9. 16267758
35. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004; 99(5): 855–9. 15128350
36. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet. 2004; 364(9432): 417–22. 15288739
37. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML, High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013; 339(6122): 966–71. doi: 10.1126/science.1228160 23430656
38. Hagan LM, Wolpe PR, Schinazi RF, Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol. 2013; 21(12): 625–33. doi: 10.1016/j.tim.2013.09.008 24238778
39. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P, Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013; 57 Suppl 2: S39–45. doi: 10.1093/cid/cit296 23884064
40. Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, et al. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Glob Health. 2014; 2(9): e541–9. doi: 10.1016/S2214-109X(14)70188-3 25304421
41. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N, Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(8): 558–66. doi: 10.7326/0003-4819-157-8-201210160-00006 23070489
42. Spradling PR, Tong X, Rupp L, Moorman AC, Lu M, Teshale EH, et al. Trends in HCV RNA testing among HCV antibody positive persons in care, 2003–2010. Clin Infect Dis. 2014; 59(7): 976–81. doi: 10.1093/cid/ciu509 24991025
43. Kesli R, Polat H, Terzi Y, Kurtoglu MG, Uyar Y, Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol. 2011; 49(12): 4089–93. doi: 10.1128/JCM.05292-11 21940466
44. Dore GJ, Ward J, Thursz M, Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014; 21 Suppl 1: 1–4. doi: 10.1111/jvh.12253 24713003
45. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012; 61(RR-4): 1–32. 22895429
46. Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011; 11(6): 1188–200. doi: 10.1111/j.1600-6143.2011.03460.x 21401874
47. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ, The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013; 13: 288. doi: 10.1186/1471-2334-13-288 23799878
48. Egypt Ministry of Health. Egypt National Control Strategy for Viral Hepatitis. 2008 [cited 24 July 2014]; https://www.pasteur.fr/ip/resource/filecenter/document/01s-00002i-03t/nsp-10-april-2008-final.pdf
49. World Health Organization. Service delivery approaches to HIV testing and counselling (HTC): A strategic policy framework. 2012 [cited 27 August 2012]; http://apps.who.int/iris/bitstream/10665/75206/1/9789241593877_eng.pdf
50. World Health Organization. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). 2010 [cited 9 June 2014]; http://whqlibdoc.who.int/publications/2010/9789241599382_eng.pdf
51. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013; 58(5): 1598–609. doi: 10.1002/hep.26431 23553643
52. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013; 57 Suppl 2: S80–9. doi: 10.1093/cid/cit306 23884071
53. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014 [cited 21 July 2014]; http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf
54. Chen TY, Ding EL, Seage Iii GR, Kim AY, Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009; 49(10): 1605–15. doi: 10.1086/644771 19842982
55. Thein HH, Yi Q, Dore GJ, Krahn MD, Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22(15): 1979–91. doi: 10.1097/QAD.0b013e32830e6d51 18784461
56. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20(1 Pt 1): 15–20. 8020885
57. Chou R, Wasson N, Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158(11): 807–20. doi: 10.7326/0003-4819-158-11-201306040-00005 23732714
58. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. 2006 [cited; http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf
59. van de Ven N, Fortunak J, Simmons B, Ford N, Cooke G, Khoo S, et al. Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus. Hepatology. E-pub ahead of print. 2014. 25482139
60. World Health Organization. Access to Antiretroviral Drugs in Low- and Middle-Income Countries. 2014 [cited 29 July 2014]; http://apps.who.int/iris/bitstream/10665/128150/1/9789241507547_eng.pdf
61. Bristol-Myers Squibb. HCV Developing World Strategy. 2014 [cited 14 November 2014]; http://www.bms.com/responsibility/access-to-medicines/Pages/HCV-developing-world-strategy.aspx
62. Gilead Sciences. Chronic Hepatitis C Treatment Expansion: Generic Manufacturing for Developing Countries. 2014 [cited 30 September 2014]; http://www.gilead.com/~/media/Files/pdfs/other/HCVGenericAgreementFactSheet.pdf
63. Government of India: Controller General of Patents Designs and Trademarks. Application Number 6087/DELNP/2005 Decision. 2015 [cited 17 January 2015]; http://ipindiaservices.gov.in/decision/6087-DELNP-2005-8837/6087DNP2005.pdf
64. World Health Organization. A model quality assurance system for procurement agencies. 2007 [cited; http://apps.who.int/medicinedocs/documents/s14866e/s14866e.pdf
65. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24): 2584–93. doi: 10.1001/jama.2012.144878 23268517
66. World Health Organization. The Maputo Declaration on Strengthening of Laboratory Systems. 2008 [cited 25 January 2012]; http://www.who.int/hiv/amds/amds_maputo_dec_lab_sys.pdf
67. Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology. 2010; 51(3): 752–8. doi: 10.1002/hep.23407 20043287
68. Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS ONE. 2014; 9(3): e86461. doi: 10.1371/journal.pone.0086461 24603442
69. Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR, Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat. 2013; 20(1): 65–71. doi: 10.1111/j.1365-2893.2012.01630.x 23231086
70. Egypt Ministry of Health. Egypt Demographic and Health Survey. 2008 [cited;: http://dhsprogram.com/pubs/pdf/FR220/FR220.pdf
71. Ruisenor-Escudero H, Wirtz AL, Berry M, Mfochive-Njindan I, Paikan F, Yousufi HA, et al. Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan. Drug Alcohol Depend. 2014; 143: 127–33. doi: 10.1016/j.drugalcdep.2014.07.022 25131717
72. Hill K, Lopez AD, Shibuya K, Jha P, Interim measures for meeting needs for health sector data: births, deaths, and causes of death. Lancet. 2007; 370(9600): 1726–35. 18029005
73. Futures Institute. OneHealth Tool. 2014 [cited 10 November 2014]; http://www.futuresinstitute.org/onehealth.aspx
74. Roush S, Birkhead G, Koo D, Cobb A, Fleming D, Mandatory reporting of diseases and conditions by health care professionals and laboratories. JAMA. 1999; 282(2): 164–70. 10411198
75. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012; 54(10): 1465–72. doi: 10.1093/cid/cis227 22431808